tabalumab + bortezomib + dexamethasone

This is a **combination therapy** consisting of three agents: - **Tabalumab** is a fully human monoclonal antibody that targets and neutralizes B-cell activating factor (BAFF), a cytokine critical for B-cell survival and implicated in the pathogenesis of multiple myeloma. By blocking BAFF, tabalumab restricts the growth and adhesion of malignant plasma cells[1][3][5]. - **Bortezomib** is a small-molecule proteasome inhibitor that disrupts protein degradation, leading to apoptosis in malignant plasma cells. It is widely approved and used for multiple myeloma[1][2][4]. - **Dexamethasone** is a synthetic glucocorticoid that exerts antineoplastic and anti-inflammatory effects, commonly used to enhance efficacy of other myeloma drugs[1][2][3][4]. This combination has been studied for the *treatment of relapsed or refractory multiple myeloma* in phase 1 and phase 2 clinical trials, especially in patients who have failed prior therapies. The rationale is to exploit complementary mechanisms: immunotherapy with tabalumab, targeted protein degradation with bortezomib, and anti-proliferative/survival effects with dexamethasone[1][3][5][7].